3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lymphoma
24
Lymphoma, Non-Hodgkin
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Large B-Cell, Diffuse
13
Leukemia, Myeloid, Acute
9
Leukemia
9
Neuroblastoma
8
Leukemia, Lymphocytic, Chronic, B-Cell
8
Hodgkin Disease
8
Central Nervous System Neoplasms
8
Medulloblastoma
7
Rhabdoid Tumor
6
Recurrence
6
Multiple Myeloma
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, B-Cell, Marginal Zone
6
Burkitt Lymphoma
6
Neoplasms, Germ Cell and Embryonal
5
Lymphoma, Follicular
5
Lymphoma, B-Cell
5
Glioma
5
Brain Neoplasms
5
Sarcoma
4
Ovarian Neoplasms
4
Oligodendroglioma
4
Neoplasms
4
Lung Neoplasms
4
Immunoblastic Lymphadenopathy
4
Astrocytoma
4
Interventions
etoposide phosphate
1
enzalutamide
1
Tissue Banks
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Patient Discharge
1
Etoposide
1
Dasatinib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Brain Diseases
×
etoposide phosphate
×
Clear all
NCT05762419
2026-01-28
FUS Etoposide for DMG
Columbia University
Phase 1
Recruiting
10 enrolled